These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21219127)

  • 21. [Epstein-Barr virus-positive diffuse large B-cell lymphoma following peripheral T-cell lymphoma, not otherwise specified: report of a case].
    Zhang F; Liu YH; Zhuang HG; Li L; Luo XL; Xu J
    Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):414-5. PubMed ID: 21055162
    [No Abstract]   [Full Text] [Related]  

  • 22. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
    Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
    Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
    Kayamori K; Shono K; Onoda M; Yokota A
    Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
    Nam SJ; Go H; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Leuk Lymphoma; 2014 Nov; 55(11):2466-76. PubMed ID: 24397616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.
    Tisi MC; Cupelli E; Santangelo R; Maiolo E; Alma E; Giachelia M; Martini M; Bellesi S; D'Alò F; Voso MT; Pompili M; Leone G; Larocca LM; Hohaus S
    Leuk Lymphoma; 2016; 57(3):628-34. PubMed ID: 26458141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary.
    Ahbeddou N; Fetohi M; Khanoussi BE; Errihani H
    Arch Gynecol Obstet; 2011 May; 283(5):1173-4. PubMed ID: 20957380
    [No Abstract]   [Full Text] [Related]  

  • 28. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
    Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
    Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
    [No Abstract]   [Full Text] [Related]  

  • 29. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
    Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
    Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
    Wang E; Papavassiliou P; Sebastian S
    Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
    Tanaka S; Nagata N; Mine S; Igari T; Kobayashi T; Sugihara J; Honda H; Teruya K; Kikuchi Y; Oka S; Uemura N
    World J Gastroenterol; 2013 Aug; 19(29):4827-31. PubMed ID: 23922484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Standard of care and new drugs for diffuse large B-cell lymphoma].
    Yamamoto K
    Rinsho Ketsueki; 2014 Oct; 55(10):1920-8. PubMed ID: 25297756
    [No Abstract]   [Full Text] [Related]  

  • 33. [A case of primary pulmonary malignant lymphoma associated with autoimmune hemolytic anemia].
    Kubota Y
    Nihon Kokyuki Gakkai Zasshi; 2006 Jun; 44(6):453-7. PubMed ID: 16841717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Hui D; Proctor B; Donaldson J; Shenkier T; Hoskins P; Klasa R; Savage K; Chhanabhai M; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2010 Sep; 51(9):1658-67. PubMed ID: 20795790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
    Yoshino T; Nakamura S; Matsuno Y; Ochiai A; Yokoi T; Kitadai Y; Suzumiya J; Tobinai K; Kobayashi Y; Oda I; Mera K; Ohtsu A; Ishikura S
    Cancer Sci; 2006 Feb; 97(2):163-6. PubMed ID: 16441428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
    Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Primary hepatic lymphoma - favorable outcome with chemotherapy plus rituximab].
    Serrano-Navarro I; Rodríguez-López JF; Navas-Espejo R; Pérez-Jacoiste MA; Martínez-González MA; Grande C; Prieto S
    Rev Esp Enferm Dig; 2008 Nov; 100(11):724-8. PubMed ID: 19159179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.